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INTRODUCTION
Graft-versus-host disease (GVHD) following liver trans-
plantation (LT) is an uncommon complication but has high
mortality and represents a major diagnostic challenge.
GVHD occurs when immunocompetent donor lymphocytes
originating from the transplanted liver undergo activation
and clonal expansion, allowing them to mount a destructive
cellular immune response against recipient tissues.
Humoral GVHD is usually seen after an ABO-mismatched
liver transplant, but cellular GVHD is directed against the
major histocompatibility complex and often results in severe
multisystem disease with high mortality.1
In 1988, Burdick et al.2 first described acute GVHD after
orthopic liver transplantation (OLT). The incidence was
reported to be 0.1% by United Networks of Organ Sharing,
however some clinical trials reported an incidence of up to
1%.1,3 Skin rash and fever are the most frequent early signs,
followed by leukopenia. The mortality rate of acute GVHD
following OLT exceeds 75%.4 In most cases, death results
from overwhelming sepsis or gastrointestinal bleeding as a
consequence of bone-marrow involvement.4
It appears worthwhile to analyze our case against the
background of a broad literature review, because of the low
incidence of GVHD after LT.
CASE REPORT
A 64-year-old male with hepatitis C virus infection,
alcohol-related cirrhosis and hepatocellular carcinoma in
segments V, VI and VIII received a liver transplant from an
ABO-identical (blood group A) 53-year-old male cadaveric
donor. The donor was cytomegalovirus-seronegative and
toxoplasma-seropositive. The recipient was cytomegalo-
virus-seropositive and toxoplasma-seropositive and had a
body mass index of 24.5 kg/m2. The Child–Pugh score was
A6 and the model end-stage liver disease score was 10.
During transplantation, 2 units of concentrated red cells and
4 units of fresh frozen plasma were transfused. Initial
immunosuppressants comprised tacrolimus (through levels
8–10 ng/ml) and Corticosteroid (500 mg methylpredniso-
lone intraoperatively, 250 mg postoperatively, 1 mg/kg
body weight on days 1 to 4, 0.5 mg/kg body weight on
day 5, 0.4 mg/kg body weight on days 6 to 10, then
tapering).
On day 9, an increase in hepatic enzymes aspartate
aminotransferase and alanine aminotransferase was identi-
fied from a hepatic biopsy, where acute cellular rejection
was diagnosed. The postoperative laboratory examinations
are shown in detail in Tables 1 and 2.
The treatment was steroid pulse therapy using 500 mg
methylprednisolone on five consecutive days. Sixteen days
later, a new hepatic biopsy showed regression of the
rejection. After recovery in timely fashion the patient was
discharged home on day 25. The patient was readmitted on
day 31 and presumptive diagnosis of GVHD was made on
clinical grounds, which was supported by the presence of a
skin rash and generalized maculopapular eruption (most
accentuated on the abdomen, trunk and face) in conjunction
with erythema and palm rash, fever, severe leukopenia
(0.45 mil/mm3), anemia, low hemoglobin and low blood
pressure levels and watery diarrhea. Skin biopsies were
consistent with GVHD, showing vacuolar degeneration of
the basal layer of the epithelium, epidermal infiltration by
lymphocytes and necrotic eosinophilic keratinocytes. Other
findings were as follows: spongiosis, basal cell hydropic
changes, many apoptotic keratinocytes, and lymphocytic
exocytosis (including satellite-cell necrosis) in the epidermis.
Furthermore, there was subepidermal cleft formation (grade
III of acute GVHD) (Figures 1 and 2). A myelogram
performed a few days later revealed a hypoplastic bone
marrow resulting in aplasia. The main microscopic features
were single-cell necrosis (apoptosis) in themucosa of all three
organs. No specific infectious agents could be identified in
those samples. The gastric mucosa had some gland abscesses
and partial mucosal denudation. Genomic DNA from
recipient peripheral blood showed the presence of both
donor and recipient antigens on day 32 (chimerism). Flow
cytometry indicated the level of donor T-lymphocyte macro-
chimerism to be between 3 and 4%. The patient received 1 g
intravenous methylprednisolone for 3 days, starting on day
31, and antithymocyte globulin (500 mg i.v. on five con-
secutive days): there was no improvement in the skin rash.
On day 36, there was a progressive worsening of the
patient’s clinical condition, with pulmonary and renal
insufficiency, agranulocytosis, and, subsequently, multi-
organ failure resulting in death.
DISCUSSION
In 1966, Billigham5 described the essential requirements
for the development of GVHD: first, the graft must contain
immunologically competent cells; second, the recipient must
be recognized as foreign by the graft; and, third, the
recipient must be unable to reject the graft before it mounts
an effective immune response.
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The pathogenesis of acute GVHD involved clearly
proinflammatory cytokine release caused by leukocyte
destruction. Interleukin-2 was demonstrated to be a key
mediator for the development of GVHD. Hence, its
membrane-bound ligand, CD25, appears to be an attractive
target for drug intervention in GVHD. There are three
reported cases of patients in whom anti-CD25 monoclonal
antibodies have been administered. All three patients were
cured of GVHD.6,7
Tumor necrosis factor-alpha also plays an important role
in the pathogenesis of GVHD and may therefore be an
interesting therapeutic target. There are some single reports
of the use of infliximab, a chimeric anti-tumor necrosis
factor-alpha monoclonal antibody, against GVHD. Despite
reducing some of the symptoms and organ manifestations,
reported outcomes were poor.8,9
Chimerism, the coexistence of genetically different cells in
the same organ or organism, was first recognized after LT in
1969 and may include replacement donor reticuloendothe-
lial cells, endothelium, bile-duct epithelium, and hepato-
cytes with recipient tissue.10,11 Systemic microchimerism,
where donor-derived cells (especially hematopoietic cells)
establish themselves in the recipients, was first demon-
strated after LT in 1992.12
As an estimated 109–1010 donor lymphoid cells are
transplanted together with a liver graft,13 chimerism
regularly occurs over a period of 3–4 weeks after LT.
Thus, GVHD predominantly occurs in the first few weeks
after LT.
It is assumed that macrochimerism with more than 1% of
circulating nucleated cells of donor origin in the peripheral
blood commonly precedes GVHD but this is not totally
accepted at the time of diagnosis.14,15
Two main risk factors for the development of GVHD after
OLT have been determined: human leukocyte antigen
(HLA) matching between the donor and the recipient; and
the recipient’s age.1 Donor–recipient compatibility for HLA-
B but not for HLA-A or DR was identified as a significant
risk factor for the development of GVHD.16 With an HLA-A
and HLA-B mismatch of 3–4, the relative risk of the
development of GVHD after OLT was estimated to be 1%.
Relative risk increased to 7% in the presence of 0–1 HLA-A
and HLA-B mismatches, and reached approximately 12.5%
in the additional presence of 0–1 HLA-DR mismatches.1
With increasing age of the recipient the risk of GVHD
seems to rise. It was reported to be nine-fold higher for
recipients older than 65 years of age compared with
younger recipients,3 as was shown in our case. Concerning
the risk factors for developing GVHD after LT, no
correlation of autoimmune hepatitis or alcoholic liver
cirrhosis in combination with glucose intolerance and
hepatocellular carcinoma could be detected in our case.
Usually, the first signs of GVHD are skin lesions
manifesting as a skin rash.17 GVHD can also affect other
organs systems such as lung, intestine and brain.18
Pancytopenia, which is uncommon in GVHD after stem-
cell transplantation, manifests regularly in patients with
GVHD after LT.14 GVHD after OLT occurs less frequently
than it does after stem-cell transplantation, but mortality is
markedly higher. Basically in stem-cell transplantation the
liver is a frequent target organ of GVHD, it is the origin of T
cells which regularly affect the bone marrow thus leading to
pancytopenia. Importantly, macrochimerism is only a
diagnostic tool in GVHD after LT.
Figure 2 - Skin biopsy stained with hematoxylin–eosin at 620
magnification, showing the epidermis with basal cell hydropic
changes, satellite-cell necrosis (near the dermis) and multiple
apoptotic keratinocytes.
Figure 1 - Skin biopsy stained with hematoxylin–eosin at 620
magnification, showing many apoptotic keratinocytes, lympho-
cytic exocytosis and spongiosis in addition to the subepidermal
cleft.
Table 1 - Postoperative laboratory investigation.
S. Urea
S. Creatinine
18
0.81
mg/dl
mg/dl
INR
Platelets
1.4
95 mil/mm3
Hematocrit
Heamoglobin
Leukocytes
33.9
11.17
3.62
%
g/dl
mil/mm3
S. Sodium
S. Potassium
S. Glucose
144
3.7
89
mEq/L
mEq/L
mg/dl
Total Billirubin
Direct Billirubin
AST
ALT
0.95
0.46
56
35
mg/dl
mg/dl
U/L
U/L
S. – serum; INR – international normalized ratio; AST – aspartate
aminotransferase; ALT – alanine aminotransferase.
Graft vs Host Disease; Liver Transplantation
Chaib E et al.
CLINICS 2011;66(6):1115-1118
1116
In many cases, the first manifestation of the immune
reaction of donor lymphoid tissue against host tissue occurs
in the skin. A maculopapular eruption can be a clue to the
diagnosis and may facilitate early modification of the
therapeutic strategy. Differential diagnosis of skin symptoms
includes drug-induced eruptions and viral infections. An
accurate diagnosis can be achieved by using specific histolo-
gical and immunohistochemical criteria.19,20 Histological
changes include the following: in grade I, lymphocytic
infiltrates in the upper dermis without epidermal changes; in
grade II, vacuolization of basal cells; in grade III, subepidermal
clefts through confluence of basal vacuolization; and, in grade
IV, massive necrosis of keratinocytes resembling toxic
epidermal necrolysis GVHD.21
Our patient had an indisputable form of GVHD with the
entire spectrum of signs and symptoms. On day 31, the
patient developed a fever, a skin rash, diarrhea, profound
leukopenia, anemia, low hemoglobin and low blood
pressure levels. A skin biopsy showed histological signs
of GVHD, such as spongiosis, basal cell hydropic changes,
many apoptotic keratinocytes and lymphocytic exocytosis
(including satellite-cell necrosis) in the epidermis.
Furthermore, there was a subepidermal cleft formation
(grade III of acute GVHD). The differential diagnosis
can be difficult, as many other causes of these symptoms
must be considered in the post-transplantation phase,
most importantly, acute organ rejection and infectious
complications.22
We failed to demonstrate bacterial, viral and fungal
causes of gastrointestinal symptoms and the histology of
resected specimens was consistent with GVHD.
We test peripheral blood for macrochimerism upon
readmission of a patient showing typical symptoms of
GVHD, and we routinely treat such cases as GVHD if
peripheral blood chimerism is .1%, whilst supporting
evidence for the diagnosis is sought.
Standard treatment of GVHD comprises increased immu-
nosuppression with high-dose steroids and antibody pre-
parations such as antithymocyte globulin, antilymphocyte
globulin and Prednisolone. There is no evidence that
steroids alone are effective in GVHD.14,23,24,25
Our case was subjected to treatment with methylpredni-
solone and antithymocyte globulin, which was clearly
ineffective.
As far as the treatment is concerned, the data suggest that
an early start to therapy is no determinant of outcome.
Broad antibiotic and antifungal prophylaxis is pivotal,
because septic complications are frequent in GVHD.26
Another issue relates to the treatment of GVHD. It may be
reasonable to focus treatment on the restoration of the host’s
immune system. Thus, there are recent reports of three
patients with GVHD after OLT in whom immunosuppres-
sion was stopped. Two of them survived, indicating a better
outcome with this therapeutic strategy,16,27 by inducing a
host-versus-graft alloimmune response against host-reactive
donor-derived cells. Moreover, withdrawal of immunosup-
pression may help the recipient’s immune system to
reconstitute itself, thereby reducing the risk of infection.
On the other hand, with regard to the risk of developing
uncontrollable rejection, it seems that in patients with a
peripheral chimerism of more than 10% after OLT,
immunosuppressants can be reduced or even withdrawn
without any increased risk of rejection.28
Another theoretical option that can be considered for
GVHD after LT is re-transplantation. Basically, GVHD
might be terminated by just removing the graft. However,
so far there are no data in the literature supporting the idea
of eliminating the donor-aggressive graft as an effective
therapeutic option. One of the major doubts relates to the
fact that the donor-reactive alloimmune response is no
longer generated by the liver itself, but is generated by
donor cells, which have already spread into the periphery
and bone marrow of the host.29
In conclusion, although acute GVHD is rare complication
of liver transplantation and the mortality is still very high,
skin lesions represent an important tool for early diagnosis.
The prognosis remains poor, and further research is
needed to both clarify the pathogenesis of GVHD and
Table 2 - Postoperative laboratorial investigation.
Immediately
Postoperative 5th PO 10th PO 25th PO
31st PO
(ICU Read-
mission)
33th PO
(GVHD
Diagnosis 36th PO
S. Urea
S. Creatinine
41
0,77
45
0,55
29
0,71
42
1,02
76
1,25
69
1,27
109
2,56
mg/dl
mg/dl
INR
Platelets
3,2
110
1,60
NM
1,6
96
1,1
114
1,2
53
1,5
57
1,8
284
-
mil/mm3
Hematocrit
Heamoglobin
Leukocytes
32.9
10,7
10,65
(Neutrophil-
88,50%)
34.1
10,9
12,55
(Neutrophil-
78,8%, Eosinophil
9,2%)
29.4
9,6
9,56
(Neutrophil-93%,
Segmented 83%)
28.4
9,5
3,18
28.0
9,2
0,45
20.1
6,6
0,1
23.1
7,4
43,36
(Neutrophil-93,%,
Monocytes 3,0%,
Lymphocutes 3,7%)
%
g/dl
mil/mm3
S. Sodium
S. Potassium
S. Glucose
140
4,6
-
138
3
96
142
3,6
93
135
4,9
-
134
4,9
-
136
4
-
135
4,4
-
mEq/L
mEq/L
mg/dl
Total Bilirubin
Direct Bilirubin
AST
ALT
3,89
2,25
2308
1842
6,71
4,74
136
933
9,08
7,48
213
319
2,57
1,62
50
60
1,83
1,32
60
64
1,42
0,57
57
31
2,93
2,42
208
49
mg/dl
mg/dl
U/L
U/L
S. – serum; INR – international normalized ratio; AST – aspartate aminotransferase; ALT – alanine aminotransferase; NM – not mentioned; ICU – intensive
care unit; GVHD – graft versus host disease.
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provide new therapeutic agents for treating this condition
effectively.
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